← Leaderboards
Luigi Puglielli
University Of Wisconsin-Madison
$13,206,203
Attributed
$16,470,397
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,470,397 · 9
VA$0 · 3
By mechanism
R01$10,233,565 · 5
RF1$5,425,115 · 2
P50$811,717 · 2
I01$0 · 3
Top collaborators
- Lingjun Li4 shared
- Rozalyn M. Anderson1 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Lingjun Li$21,786,496
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMolecularEventAffectBiochemicalPathway InteractionsPlayReportingGeneticAgingS DiseaseMouse ModelGenerationsBrainPhenotypeLinkNeuronsNeuropathologyPathogenesisNerve DegenerationAcetyltransferaseRisk FactorsAnimalsAcetylation
Grant awards (47)
Creating a region- specific biomolecular atlas of the brain of Alzheimerâs disease$729,769
R01 · FY2025 · AG
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?$401,396
R01 · FY2025 · NS · contact PI
ATase1 and ATase2, proteostasis, and neurological diseases$300,344
R01 · FY2025 · GM · contact PI
Creating a region- specific biomolecular atlas of the brain of Alzheimerâs disease$747,773
R01 · FY2024 · AG
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?$432,612
R01 · FY2024 · NS · contact PI
ATase1 and ATase2, proteostasis, and neurological diseases$300,344
R01 · FY2024 · GM · contact PI
Creating a region- specific biomolecular atlas of the brain of Alzheimerâs disease$752,438
R01 · FY2023 · AG
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?$445,993
R01 · FY2023 · NS · contact PI
ATase1 and ATase2, proteostasis, and neurological diseases$300,344
R01 · FY2023 · GM · contact PI
Creating a region- specific biomolecular atlas of the brain of Alzheimerâs disease$753,993
R01 · FY2022 · AG
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?$445,993
R01 · FY2022 · NS · contact PI
Novel mechanisms for Alzheimer disease prevention and or treatment$0
I01 · FY2022 · VA · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?$441,315
R01 · FY2021 · NS · contact PI
Novel mechanisms for Alzheimer disease prevention and or treatment$0
I01 · FY2021 · VA · contact PI
Novel mechanisms for Alzheimer disease prevention and or treatment$0
I01 · FY2020 · VA · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT-1/SLC33A1?$330,978
R01 · FY2019 · NS · contact PI
Novel mechanisms for Alzheimer disease prevention and or treatment$0
I01 · FY2019 · VA · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT-1/SLC33A1?$330,978
R01 · FY2018 · NS · contact PI
Acetyl-CoA flux and mitochondrial adaptation: a pathogenic role in aging and AD?$3,544,415
RF1 · FY2017 · AG · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT-1/SLC33A1?$330,978
R01 · FY2017 · NS · contact PI
Proteostasis in the aging and Alzheimer's disease brain: are the ATases novel targets?$1,880,700
RF1 · FY2016 · AG · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT-1/SLC33A1?$330,978
R01 · FY2016 · NS · contact PI
Novel mechanisms for Alzheimer's disease prevention and/or treatment$0
I01 · FY2016 · VA · contact PI
Spastic paraplegia, neurodegeneration and autism: possible role for AT-1/SLC33A1?$330,978
R01 · FY2015 · NS · contact PI
Novel mechanisms for Alzheimer's disease prevention and/or treatment$0
I01 · FY2015 · VA · contact PI
Novel mechanisms for Alzheimer's disease prevention and/or treatment$0
I01 · FY2014 · VA · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$121,244
P50 · FY2013 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$121,243
P50 · FY2013 · AG · contact PI
Novel mechanisms for Alzheimer's disease prevention and/or treatment$0
I01 · FY2013 · VA · contact PI
Aging and Alzheimer's Disease Potential Link with IGF1-R$286,660
R01 · FY2012 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$137,721
P50 · FY2012 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$17,392
P50 · FY2012 · AG · contact PI
p75NTR-Ceramide Signaling in Alzheimer?s Disease$0
I01 · FY2012 · VA · contact PI
Aging and Alzheimer's Disease Potential Link with IGF1-R$286,660
R01 · FY2011 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$137,864
P50 · FY2011 · AG · contact PI
p75NTR-Ceramide Signaling in Alzheimer?s Disease$0
I01 · FY2011 · VA · contact PI
p75NTR-Ceramide Signaling in Alzheimer?s Disease$0
I01 · FY2011 · VA · contact PI
Aging and Alzheimer's Disease Potential Link with IGF1-R$298,231
R01 · FY2010 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$139,399
P50 · FY2010 · AG · contact PI
Aging and Alzheimer's Disease Potential Link with IGF1-R$301,243
R01 · FY2009 · AG · contact PI
BACE1 acetylation: potential target for the prevention of late-onset AD?$136,854
P50 · FY2009 · AG · contact PI
p75NTR-Ceramide Signaling in Alzheimer?s Disease$0
I01 · FY2009 · VA · contact PI
Aging and Alzheimer's Disease Potential Link with IGF1-R$301,243
R01 · FY2008 · AG · contact PI
Second messenger ceramide in Alzheimer's disease$248,648
R01 · FY2007 · NS · contact PI
Second messenger ceramide in Alzheimer's disease$256,075
R01 · FY2006 · NS · contact PI
Second messenger ceramide in Alzheimer's disease$262,238
R01 · FY2005 · NS
Second messenger ceramide in Alzheimer's disease$285,363
R01 · FY2004 · NS